Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension

被引：85
|
作者：
Schwartz, Bryan G. [1 ]
Kloner, Robert A. [1 ,2 ]
机构：
[1] Hosp Good Samaritan, Inst Heart, Los Angeles, CA 90017 USA
[2] Univ So Calif, Keck Sch Med, Div Cardiovasc Med, Dept Internal Med, Los Angeles, CA 90033 USA
来源：
CIRCULATION | 2010年 / 122卷 / 01期
关键词：
drug combinations; nitroglycerin; pharmacokinetics; sex; vasodilation; HEALTHY MALE-SUBJECTS; INHALED NITRIC-OXIDE; ARTERIAL-HYPERTENSION; SILDENAFIL CITRATE; ORAL SILDENAFIL; CLINICAL-TRIALS; PHARMACOKINETIC INTERACTIONS; HEMODYNAMIC INTERACTION; CARDIOVASCULAR SAFETY; IN-VITRO;
D O I：
10.1161/CIRCULATIONAHA.110.944603
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：88 / 95
页数：8
相关论文
共 50 条
  • [41] Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction
    Dorsey, Philip
    Keel, Christopher
    Klavens, Meghan
    Hellstrom, Wayne J. G.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1109 - 1122
  • [42] Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction
    Yafi, Faysal A.
    Sharlip, Ira D.
    Becher, Edgardo F.
    [J]. SEXUAL MEDICINE REVIEWS, 2018, 6 (02) : 242 - 252
  • [43] Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
    Jiann, Bang-Ping
    [J]. UROLOGICAL SCIENCE, 2016, 27 (02) : 66 - 70
  • [44] An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors
    Bruzziches, Roberto
    Francomano, Davide
    Gareri, Pietro
    Lenzi, Andrea
    Aversa, Antonio
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1333 - 1344
  • [45] Oral Therapies for Pulmonary Arterial Hypertension Endothelin Receptor Antagonists and Phosphodiesterase-5 Inhibitors
    Channick, Richard
    Preston, Iona
    Klinger, James R.
    [J]. CLINICS IN CHEST MEDICINE, 2013, 34 (04) : 811 - +
  • [46] Haemodynamic profiles in type 2 pulmonary hypertension influence response to phosphodiesterase-5 inhibitors
    Patricia Alves, P.
    Marinho, A. V.
    Domingues, C.
    Ferreira, J. A.
    Milner, J.
    Baptista, R.
    Franco, F.
    Castro, G.
    Pego, M.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 406 - 407
  • [47] HAEMODYNAMIC PROFILES IN TYPE 2 PULMONARY HYPERTENSION INFLUENCE RESPONSE TO PHOSPHODIESTERASE-5 INHIBITORS
    Alves, Patricia
    Baptista, Rui
    Marinho, Antonio
    Castro, Graca
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1957 - 1957
  • [48] Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors
    Matot, I
    Gozal, Y
    [J]. CHEST, 2004, 125 (02) : 644 - 651
  • [49] Sexually transmitted infection in HIV-positive men with erectile dysfunction using phosphodiesterase-5 inhibitors
    McCarty, E. J.
    Quinn, K.
    Dinsmore, W. W.
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 (06) : 455 - 455
  • [50] Combination of Psychological Intervention and Phosphodiesterase-5 Inhibitors for Erectile Dysfunction: A Narrative Review and Meta-Analysis
    Schmidt, Hannah M.
    Munder, Thomas
    Gerger, Heike
    Fruehauf, Sarah
    Barth, Juergen
    [J]. JOURNAL OF SEXUAL MEDICINE, 2014, 11 (06): : 1376 - 1391
12345